Skip to content

Repligen RGEN Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

TEC
Bio-TechneTECH
-$22.1M-168%
Revvity logo
RevvityRVTY
-$74.69M-115%
Danaher logo
DanaherDHR
-$322M-38.2%
Agilent Technologies logo
Agilent TechnologiesA
-$151M-45.2%
Charles River Laboratories logo
Charles River LaboratoriesCRL
-$83.76M-649%
STERIS logo
STERISSTE
$74.3M+71.2%

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's change in accrued liabilities?
Repligen (RGEN) reported change in accrued liabilities of -$12.66M in Q1 2026.
How has Repligen's change in accrued liabilities changed year-over-year?
Repligen's change in accrued liabilities decreased by 800.3% year-over-year, from $1.81M to -$12.66M.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.